Cervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?.
- Author:
Soo Ho CHUNG
1
Author Information
- Publication Type:Review
- Keywords: Early detection of cancer; Human papilloma virus; Perimenopause; Uterine cervical neoplasms
- MeSH: Cervical Intraepithelial Neoplasia; Early Detection of Cancer; Female; Humans*; Incidence; Korea; Mass Screening*; Methods; Papillomaviridae; Perimenopause*; Sensitivity and Specificity; Uterine Cervical Neoplasms*
- From:Journal of Menopausal Medicine 2016;22(2):65-70
- CountryRepublic of Korea
- Language:English
- Abstract: Cervical cancer is the third most prevalent cancer in women around the world. Recently in Korea, the incidence of cervical cancer has decreased, but in all stages of cervical intraepithelial neoplasia (CIN), CIN has shown a 91% increase from 1999 to 2008. Persistent human papillomavirus (HPV) infection has been found to be the main cause of cervical cancer. HPV types 16 and 18 have been found in 70% of cervical cancer patients around the world. Cervical cancer screening such as cytology has limitations in terms of sensitivity and specificity. A discussion about the need for the HPV test is becoming active in order to compensate for the limitation of cytology. After the role of HPV in cervical cancer was identified, the importance of HPV detection test as a screening was emphasized. Several tests have been developed and each test has its own advantages and disadvantages, and new test method to overcome the disadvantages is still being developed. Today's guidelines and tests are those you would choose from among the large number of cervical cancer screening guidelines and tests, based on the consideration that the selected guidelines and the test are effective.
